Singapore Institute of Advanced Medicine Holdings Ltd. (SGX:9G2)

SGXC:9G2 Statistics

Total Valuation

SGXC:9G2 has a market cap or net worth of SGD 43.10 million. The enterprise value is 97.93 million.

Market Cap	43.10M
Enterprise Value	97.93M

Important Dates

The last earnings date was Wednesday, October 29, 2025.

Earnings Date	Oct 29, 2025
Ex-Dividend Date	n/a

Share Statistics

SGXC:9G2 has 1.23 billion shares outstanding. The number of shares has increased by 27.90% in one year.

Current Share Class	1.23B
Shares Outstanding	1.23B
Shares Change (YoY)	+27.90%
Shares Change (QoQ)	+0.78%
Owned by Insiders (%)	27.88%
Owned by Institutions (%)	9.75%
Float	315.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.74
PB Ratio	0.77
P/TBV Ratio	0.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.62
EV / Sales	6.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.07

Financial Position

The company has a current ratio of 0.31, with a Debt / Equity ratio of 1.05.

Current Ratio	0.31
Quick Ratio	0.29
Debt / Equity	1.05
Debt / EBITDA	n/a
Debt / FCF	-5.39
Interest Coverage	-7.46

Financial Efficiency

Return on equity (ROE) is -39.37% and return on invested capital (ROIC) is -11.22%.

Return on Equity (ROE)	-39.37%
Return on Assets (ROA)	-10.30%
Return on Invested Capital (ROIC)	-11.22%
Return on Capital Employed (ROCE)	-20.21%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.12
Inventory Turnover	82.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.88% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-46.88%
50-Day Moving Average	0.03
200-Day Moving Average	0.06
Relative Strength Index (RSI)	51.11
Average Volume (20 Days)	334,650

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SGXC:9G2 had revenue of SGD 15.71 million and -27.05 million in losses. Loss per share was -0.03.

Revenue	15.71M
Gross Profit	6.77M
Operating Income	-21.70M
Pretax Income	-27.05M
Net Income	-27.05M
EBITDA	-12.72M
EBIT	-21.70M
Loss Per Share	-0.03

Balance Sheet

The company has 3.38 million in cash and 58.21 million in debt, giving a net cash position of -54.83 million or -0.04 per share.

Cash & Cash Equivalents	3.38M
Total Debt	58.21M
Net Cash	-54.83M
Net Cash Per Share	-0.04
Equity (Book Value)	55.64M
Book Value Per Share	0.05
Working Capital	-12.03M

Cash Flow

In the last 12 months, operating cash flow was -10.65 million and capital expenditures -147,785, giving a free cash flow of -10.80 million.

Operating Cash Flow	-10.65M
Capital Expenditures	-147,785
Free Cash Flow	-10.80M
FCF Per Share	-0.01

Margins

Gross margin is 43.11%, with operating and profit margins of -138.15% and -172.22%.

Gross Margin	43.11%
Operating Margin	-138.15%
Pretax Margin	-172.17%
Profit Margin	-172.22%
EBITDA Margin	-81.00%
EBIT Margin	-138.15%
FCF Margin	n/a

Dividends & Yields

SGXC:9G2 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.90%
Shareholder Yield	n/a
Earnings Yield	-62.77%
FCF Yield	-25.05%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SGXC:9G2 has an Altman Z-Score of -1.47 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.47
Piotroski F-Score	2